pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE

Inclusion Criteria:

* Male or female patients aged 18 years or older;
* Histologically confirmed stage III resectable or stage IV metastatic cutaneous melanoma with confirmed BRAF mutation, for whom the treating physician took the decision to initiate treatment with dabrafenib and trametinib before entering the study;
* Treatment with Dabrafenib and Trametinib was initiated no longer than 4 weeks (28 days) prior to written informed consent for this study;
* Performance status ≤ 2 by Eastern Cooperative Oncology Group (ECOG) scale;
* Patient is willing and able to participate in the study;
* Written informed consent for study participation.

Exclusion Criteria:

* Patients with a life expectancy of less than 3 months at the time of melanoma diagnosis, per the investigator's judgment.
* Patients participating in any interventional clinical trial that includes investigational or marketed products at the time of enrollment. (Patients participating in other investigator initiated or other non-interventional study \[NIS\] can be included as long as their standard of care is not altered by the study).
* Patients on active treatment for malignancies other than melanoma at the time of enrollment.